Zamann Pharma Support logo

Siedlerstraße 7 | 68623 Lampertheim, Germany

info@zamann-pharma.com

Request an appointment now

CSV Documentation in 2026: GMP Compliance, Data Integrity, and Inspection Readiness

This article explains how CSV Documentation supports GMP compliance in computerized systems, focusing on validation traceability, IQ OQ PQ documentation, and data integrity requirements aligned with FDA 21 CFR Part 11 and EU Annex 11 expectations.
  • Blog, Validation and Qualification
Pharmaceutical validation documentation workflow for Computer System Validation (CSV) in GMP computerized systems, highlighting validation traceability matrix, IQ OQ PQ documentation, and compliance with GAMP 5 validation and data integrity standards.

AI in Clinical Trials Faces Trust Crisis; Regulatory Uncertainty Grows

A recent survey by the Pistoia Alliance at the Clinical Trials Technology Congress (CTTC) in London shows that trust issues and regulatory uncertainty continue to slow artificial intelligence adoption in clinical trials. Although AI already delivers early value in clinical
  • News
AI in Clinical Trials Faces Trust Crisis; Regulatory Uncertainty Grows

FDA Quietly Rewrites Drug Repurposing Rules; Pharma Data Validation Suddenly Becomes Critical

The FDA is urging pharmaceutical companies to re-examine decades of clinical and real-world data using AI and advanced analytics to identify new uses for existing drugs. Published on May 29, 2026, this initiative highlights how legacy datasets may still hold
  • News
FDA Quietly Rewrites Drug Repurposing Rules; Pharma Data Validation Suddenly Becomes Critical

Sterile Area Maintenance in 2026: Inspection Readiness

Sterile Area Maintenance in 2026 examines how cleanroom control failures impact GMP inspection outcomes. This article explains key contamination risks, regulatory expectations, and maintenance practices that influence sterile manufacturing compliance and inspection readiness in pharmaceutical environments.
  • Blog, Quality Management System
Process flow diagram showing how cleanroom maintenance failures escalate into contamination risk during sterile manufacturing GMP inspections

Pharma Goes Digital; GMP Compliance Will Never Be the Same

A major shift is underway in pharmaceutical manufacturing as companies move toward hybrid cloud infrastructure, advanced analytics, and digital quality systems. Speaking on the industry's evolving landscape, Mike Hennessy Jr. of MJH Life Sciences highlighted how hybrid cloud architectures, statistical
  • News
Pharma Goes Digital; GMP Compliance Will Never Be the Same

China Biotech Forces Pharma Power Shift; $10B Pfizer Deal Marks Turning Point

Pfizer’s $10 billion licensing deal with Innovent, alongside rising U.S. debate over expanding COINS Act restrictions on China biotech investment, signals a structural shift in global pharma strategy. The announcement, combined with Astellas’ Xtandi patent cliff response and ASCO scrutiny
  • News
China Biotech Forces Pharma Power Shift; $10B Pfizer Deal Marks Turning Point

SOP Checklist in 2026: Red Flags Found During GMP Audits

This article explains how SOP Checklist failures influence GMP inspection outcomes and how structured compliance systems improve audit readiness. It highlights real inspection patterns, document control gaps, and practical strategies to strengthen pharmaceutical quality system performance.
  • Blog, Quality Management System
GMP inspection readiness checklist in pharmaceutical laboratory showing SOP compliance pharma workflow, document control, and audit preparation under quality system standards.

Pharma Shifts From Validation to Speed; What Changed Behind It

As development timelines shrink across the pharmaceutical industry, companies are placing greater emphasis on speed, scalability and manufacturing certainty. The trend, highlighted at CPHI Japan 2026, signals mounting pressure on drugmakers and CDMOs to deliver faster without compromising GMP compliance,
  • News
Pharma Shifts From Validation to Speed; What Changed Behind It

FDA One-Day Inspections Trigger Compliance Shock; AI Shift Reshapes Global Pharma Oversight

FDA launches one-day inspections and expands AI systems Elsa 4.0 and HALO at its headquarters in the United States, introducing a major shift in global pharmaceutical regulation. The move accelerates risk-based oversight and structured-data review, reshaping GMP expectations for manufacturers
  • News
FDA One-Day Inspections Trigger Compliance Shock; AI Shift Reshapes Global Pharma Oversight

ASCO 2026 CAR-T Breakthrough Expands Scale, Don’t Miss This GMP Shift

At ASCO 2026 in Chicago, ASCO 2026, Wondercel Therapeutics, founder Frank Fan, also the inventor of Carvykti, presented early clinical and manufacturing data on a novel allogeneic CAR-T cell therapy platform called Revo-U. The approach aims to overcome key GMP
  • News
ASCO 2026 CAR-T Breakthrough Expands Scale, Don’t Miss This GMP Shift